Publication Cover
Drying Technology
An International Journal
Volume 42, 2024 - Issue 4
43
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Quality by design based synthesis and characterization of novel maleyl functionalized albumin solid dry powder for pulmonary targeting

ORCID Icon &
Pages 712-727 | Received 24 Aug 2023, Accepted 07 Jan 2024, Published online: 24 Jan 2024
 

Abstract

Dry powder inhalers (DPIs) are propellant-free portable devices used to provide medicines to the lung. Lactose monohydrate is the most common drug carrier for DPIs. However, the lactose monohydrate exhibits several limitations such as Maillard reaction, hypersensitivity, and lactose intolerance. Hence, there is a need to develop a better alternative carrier excipient that offers all the benefits with no or minimal limitations. In this investigation, we synthesized and evaluated a novel albumin-based carrier excipient for dry powder application via albumin modification by the QbD approach. We conjugated the maleic group on the lysine residue of albumin. Maleic conjugated BSA (ɱ+BSA) was investigated using instrumental techniques FTIR, NMR, FESEM, and XRD. Characterization of ɱ+BSA displays a zeta potential of −28 ± 0.4 mV, an emitted fraction (EF) of 91.29 ± 0.6%, fine particle fraction (FPF) of 74.31 ± 0.8%, mean mass aerodynamic diameter (MMAD) of 1.20 ± 1.6 µm, and geometric standard deviation (GSD) of 2.44 ± 0.34. Additionally, the ɱ+BSA was found to exhibit favorable powder characteristics, as revealed by Carr’s index, Hausner’s ratio, and BET analysis. Histological examination revealed that inhaled ɱ+BSA is safe for lung tissues in rats. These findings illustrate the exceptional features of ɱ+BSA for aerodynamic performance and appear to be a promising DPI carrier.

Graphical Abstract

Acknowledgments

The opinions presented in this publication belong to the author(s) and may not necessarily reflect the perspectives of any industries, organizations, or institutions. Gratitude is extended to SVKM's Institute of Pharmacy, Dhule for in-house research assistance. Meggle incorporation for supplying Inhalac® 500 and related information is thankfully acknowledged.

Author contributions

Conceptualization, Methodology, Formal analysis, and investigation, Writing - original draft preparation: Vinit Agnihotri; Writing - review and editing, Resources, Supervision: Dr. Ashish Gorle.

Disclosure statement

The authors declare no competing financial interest.

Additional information

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 61.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 760.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.